{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Xu G"],"pubmed_abstract":["<b>Aim:</b> The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and evaluate the potential of two novel FAK inhibitors, 10k and 10l, as therapeutic strategies for drug resistant non-small cell lung cancer (NSCLC). <b>Methods:</b> EGFR-TKI resistance in NSCLC cells was developed via stepwise drug selection. Kinases/polymerase chain reaction (PCR) arrays identified key resistance determinants, while reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry evaluated FAK messenger RNA and phosphorylation levels. Antitumor activities were"],"journal":["Cancer drug resistance (Alhambra, Calif.)"],"pagination":["57"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12635985"],"repository":["biostudies-literature"],"pubmed_title":["Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer."],"pmcid":["PMC12635985"],"pubmed_authors":["Pecoraro C","Cavazzoni A","Diana P","Assaraf YG","Vahabi M","Giovannetti E","Tiseo M","Lagrasta CAM","Xu G","Carbone D","Deng D","Zucali PA","Cascioferro SM","Avan A","Fiuji H","Peters GJ"],"additional_accession":[]},"is_claimable":false,"name":"Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer.","description":"<b>Aim:</b> The current study aims to investigate the critical role of the focal adhesion kinase (FAK) oncogenic signaling pathway in mediating drug resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) and evaluate the potential of two novel FAK inhibitors, 10k and 10l, as therapeutic strategies for drug resistant non-small cell lung cancer (NSCLC). <b>Methods:</b> EGFR-TKI resistance in NSCLC cells was developed via stepwise drug selection. Kinases/polymerase chain reaction (PCR) arrays identified key resistance determinants, while reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry evaluated FAK messenger RNA and phosphorylation levels. Antitumor activities were","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-05T17:33:10.865Z","creation":"2026-05-19T03:11:52.53Z"},"accession":"S-EPMC12635985","cross_references":{"pubmed":["41281943"],"doi":["10.20517/cdr.2025.139"]}}